Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Get an introduction to all features of this page

InflaRx NV Stock

Price
Target price
€0.73

€0.73

2.040%
0.015
2.040%
€7.49
 
06.06.25 / Tradegate WKN: A2H7A5 / Symbol: IFRX / Name: InflaRx / Stock / Small Cap /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
JavaScript chart by amCharts 3.21.15
JavaScript chart by amCharts 3.21.15
JavaScript chart by amCharts 3.21.15JS chart by amCharts
Select a timeframe to show chart data
From: to:
Zoom:
Loading data...
Your prediction
Pros and Cons of InflaRx NV in the next few years
Wizard

InflaRx NV Stock

There is an upward development for InflaRx NV compared to yesterday, with an increase of €0.015 (2.040%).
With 10 Buy predictions and not the single Sell prediction the community is currently very high on InflaRx NV.
Based on the current price of 0.73 € the target price of 7 € shows a potential of 856.28% for InflaRx NV which would more than double the current price.
For the coming years our community has positive and negative things to say abot the InflaRx NV stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Innovation" there were negative voices in the community.
What does InflaRx do?

Pros and Cons of InflaRx NV in the next few years

Pros
?
B****
?
S********** s********
?
W********* I********* f** t** n*** y****
Cons
?
M***** P*******
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Your Opinion
Legal notice

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-15

InflaRx (NASDAQ: IFRX) is a company operating in the pharmaceutical industry, focusing on the development of therapies for different inflammatory diseases. A general observation of the financial statements reveals that the company experiences negative net income and operating income. However, the company has a healthy working capital and a solid stockholder equity. It is crucial to dive deeper into the financials to uncover more insights about the company's financial health and stability.

In conclusion, InflaRx's financials reveal some positive aspects, such as their healthy working capital and stable stockholder equity. However, the company's negative net income, negative operating income, and lack of steady revenue streams raise concerns about its long-term profitability and growth potential. Investors must weigh the pros and cons carefully before considering an investment in InflaRx (IFRX).

Show more

Comments

Prediction Buy
Perf. (%) 0.21%
Target price 2.666
Change
Ends at 29.05.26

InflaRx (NASDAQ: IFRX) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $6.00 to $3.00. They now have an "outperform" rating on the stock.
Ratings data for IFRX provided by MarketBeat
Show more

Oppenheimer Holdings Inc. 
0
Report Share
29.05.25
Prediction Buy
Perf. (%) -43.04%
Target price 5.297
Change
Ends at 08.05.26

InflaRx (NASDAQ: IFRX) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $6.00 price target on the stock.
Ratings data for IFRX provided by MarketBeat
Show more

Oppenheimer Holdings Inc. 
0
Report Share
08.05.25
Prediction Buy
Perf. (%) -37.44%
Target price 8.780
Change
Ends at 29.04.26

InflaRx (NASDAQ: IFRX) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $10.00 price target on the stock.
Ratings data for IFRX provided by MarketBeat
Show more

Cantor Fitzgerald 
0
Report Share
29.04.25
Show more
Not a member yet? Sign up for free!